Mastic and Reduced Interleukin-6 Levels

• Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action.

  • 2021-09
  • RCT
  • Pharmacological research 171
  • • Charalampia Amerikanou
    • Efstathia Papada
    • Aristea Gioxari
    • Ilias Smyrnioudis
    • Stamatia-Angeliki Kleftaki
    • Evdokia Valsamidou
    • Victoria Bruns
    • Rajarshi Banerjee
    • Maria Giovanna Trivella
    • Natasa Milic
    • Milica Medić-Stojanoska
    • Amalia Gastaldelli
    • Aimo Kannt
    • George V Dedoussis
    • Andriana C Kaliora

  • PubMed: 34224858
  • DOI: 10.1016/j.phrs.2021.105753

  2 Insights on

  • Reduced Interleukin-6 Levels

  • High evidence
  • Clinical

  Although the results were not so prominent in NAFLD, miR-155 displayed a downward trend in the placebo group (p = 0.054) whereas the levels did not changed significantly in the Mastiha group in patients with less advanced fibrosis.

  Effect

  Neutral

  Effect size

  Small

  Significant

  No